Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKT3964 in Advanced/Metastatic Solid Tumors
NCT06586957Phase 1Recruiting
- Sponsor
- NiKang Therapeutics
- Start
- Sep 2024
- Primary completion
- Jan 2029
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 2
01
Overview
Phase 1, open-label trial of NKT3964 in solid tumor, ovarian cancer, endometrial cancer (EC) and 5 more (10 arms), sponsored by NiKang Therapeutics. Primary endpoints: Dose Limiting Toxicity at 28 days and Objective Response Rate at 1 year. Started Sep 2024; status: recruiting.
02
Drugs
NKT3964
03
Conditions
solid tumorovarian cancerendometrial cancer (EC)gastric cancer (GC)esophageal cancer
Beyond the preview
Go deeper on NCT06586957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06586957.